Skip to main navigation

Overview
Events & Presentations
News Releases
- For Global Media Only
- For U.S. Media Only
Corporate Governance
Stock
Financial & Filings

News Releases
Intended for U.S. Media Only

News Releases

Year

May 30, 2024

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

May 14, 2024

Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism

May 13, 2024

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial

May 9, 2024

Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024

May 2, 2024

Ascendis Pharma Reports First Quarter 2024 Financial Results

April 25, 2024

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

April 24, 2024

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

March 4, 2024

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

February 7, 2024

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

February 7, 2024

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Next page
Last page

Displaying 21 - 30 of 34

Shareholder Tools

RSS Feeds

Email Alerts

IR Contact

Footer Corporate Menu

TransCon
About us
Pipeline
Patients
Investors & News
Contact Us

Footer Copyrights Menu

Privacy Policy
Terms of Use

Ascendis, Ascendis Pharma, Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group

© December 2024 Ascendis Pharma